Published • loading... • Updated
Denecimig excels at reducing bleeds in hemophilia A patients
Summary by Hemophilia News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Denecimig excels at reducing bleeds in hemophilia A patients
Denecimig (Mim8) was significantly better than on-demand or standard preventive treatments at reducing bleeding episodes in people with hemophilia A, regardless of inhibitor status. That’s according to published data from the FRONTIER2 trial (NCT05053139), which evaluated the efficacy and safety of once-monthly and once-weekly denecimig treatment in adults and adolescents ages 12 years and older with hemophilia A. The results, “Mim8 Bispecific A…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
